Exane Derivatives’s Amicus Therapeutics FOLD Stock Holding History

Exane Derivatives’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$966	Hold	90	–	–	﹤0.01%	508
2022 Q1	$852	Hold	90	–	–	﹤0.01%	816
2021 Q4	$1.04K	Hold	90	–	–	﹤0.01%	707
2021 Q3	$859	Hold	90	–	–	﹤0.01%	879
2021 Q2	$822	Hold	90	–	–	﹤0.01%	895
2021 Q1	$889	Hold	90	–	–	﹤0.01%	746
2020 Q4	$2.08K	Hold	90	–	–	﹤0.01%	624
2020 Q3	$1.27K	Hold	90	–	–	﹤0.01%	598
2020 Q2	$1.36K	Sell	90 -1,701	-95%	-$20.7K	﹤0.01%	537
2020 Q1	$16.5K	Sell	1,791 -7,009	-80%	-$66.6K	﹤0.01%	413
2019 Q4	$91.4K	Hold	8,800	–	–	0.02%	327
2019 Q3	$70.6K	Hold	8,800	–	–	0.01%	348
2019 Q2	$110K	Hold	8,800	–	–	0.02%	323
2019 Q1	$120K	Hold	8,800	–	–	0.02%	276
2018 Q4	$84.3K	Hold	8,800	–	–	0.02%	333
2018 Q3	$106K	Hold	8,800	–	–	0.02%	310
2018 Q2	$137K	Buy	+8,800	New	+$133K	0.02%	295

Other funds holding FOLD

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Exane Derivatives's FOLD Position: Q2 2022 in Review

Exane Derivatives held its Amicus Therapeutics (FOLD) position steady in Q2 2022 at 90 shares worth $966. The position accounts for ﹤0.01% of the portfolio, ranked #508.

Exane Derivatives first reported a position in FOLD in Q2 2018 and has held it in 17 quarters since. The position peaked at $137K in Q2 2018. 212 funds tracked by Wall St. Rank hold FOLD as of Q2 2022.

Exane Derivatives held 90 shares of Amicus Therapeutics worth $966 as of Q2 2022.
Exane Derivatives left its Amicus Therapeutics share count unchanged in Q2 2022.
Amicus Therapeutics made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #508 holding.
Exane Derivatives first reported a position in Amicus Therapeutics in Q2 2018 and has held it in 17 quarters since.
Exane Derivatives's Amicus Therapeutics position peaked at $137K in Q2 2018.
212 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.